MXPA03011466A - Macrociclos utiles en tratamiento de enfermedades de alzheimer. - Google Patents
Macrociclos utiles en tratamiento de enfermedades de alzheimer.Info
- Publication number
- MXPA03011466A MXPA03011466A MXPA03011466A MXPA03011466A MXPA03011466A MX PA03011466 A MXPA03011466 A MX PA03011466A MX PA03011466 A MXPA03011466 A MX PA03011466A MX PA03011466 A MXPA03011466 A MX PA03011466A MX PA03011466 A MXPA03011466 A MX PA03011466A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- treatment
- alzheimer
- useful
- macrocycles
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- 150000002678 macrocyclic compounds Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29754601P | 2001-06-12 | 2001-06-12 | |
| US33308301P | 2001-11-19 | 2001-11-19 | |
| PCT/US2002/019076 WO2002100856A1 (en) | 2001-06-12 | 2002-06-12 | Macrocycles useful in the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03011466A true MXPA03011466A (es) | 2004-07-01 |
Family
ID=26970209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03011466A MXPA03011466A (es) | 2001-06-12 | 2002-06-12 | Macrociclos utiles en tratamiento de enfermedades de alzheimer. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6969709B2 (https=) |
| EP (1) | EP1404671B1 (https=) |
| JP (1) | JP2004534064A (https=) |
| AT (1) | ATE323084T1 (https=) |
| BR (1) | BR0210392A (https=) |
| CA (1) | CA2450202A1 (https=) |
| DE (1) | DE60210614T2 (https=) |
| ES (1) | ES2261699T3 (https=) |
| MX (1) | MXPA03011466A (https=) |
| WO (1) | WO2002100856A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0214736A (pt) * | 2001-12-06 | 2004-11-23 | Elan Pharm Inc | Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica e método de tratar seres humanos ou animais que sofrem de doenças ou condições |
| US7371853B2 (en) | 2003-01-07 | 2008-05-13 | Merck & Co., Inc. | Macrocyclic β-secretase inhibitors for the treatment of Alzheimer's disease |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| US7521420B2 (en) | 2003-06-18 | 2009-04-21 | Tranzyme Pharma, Inc. | Macrocyclic antagonists of the motilin receptor |
| GB0325830D0 (en) * | 2003-11-05 | 2003-12-10 | Novartis Ag | Organic compounds |
| DE602005007245D1 (https=) * | 2004-07-28 | 2008-07-10 | Schering Corp | |
| US20080132477A1 (en) * | 2005-01-13 | 2008-06-05 | Claudia Betschart | Macrocyclic Compounds Useful as Bace Inhibitors |
| GB0500683D0 (en) * | 2005-01-13 | 2005-02-23 | Novartis Ag | Organic compounds |
| KR20080015079A (ko) | 2005-04-08 | 2008-02-18 | 코멘티스, 인코포레이티드 | 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법 |
| WO2007021793A1 (en) * | 2005-08-12 | 2007-02-22 | Bristol-Myers Squibb Company | Macrocyclic diaminopropanes as beta-secretase inhibitors |
| GB0526614D0 (en) | 2005-12-30 | 2006-02-08 | Novartis Ag | Organic compounds |
| CA2656869A1 (en) * | 2006-07-20 | 2008-01-24 | Novartis Ag | Macrocyclic lactams |
| JP2009544599A (ja) * | 2006-07-20 | 2009-12-17 | ノバルティス アクチエンゲゼルシャフト | Ｂａｃｅ阻害剤として有用な大環状化合物 |
| US7678784B2 (en) | 2006-11-20 | 2010-03-16 | Bristol-Myers Squibb Company | Oxime-containing macrocyclic acyl guanidines as β-secretase inhibitors |
| US7772221B2 (en) | 2007-02-09 | 2010-08-10 | Bristol-Meyers Squibb Company | Diaminopropane derived macrocycles as inhibitors of β amyloid production |
| US20100063013A1 (en) * | 2007-03-26 | 2010-03-11 | Renata Oballa | Cathepsin cysteine protease inhibitors |
| US7732434B2 (en) | 2007-04-20 | 2010-06-08 | Bristol-Myers Squibb Company | Macrocyclic acyl guanidines as beta-secretase inhibitors |
| US20160022649A1 (en) * | 2013-03-15 | 2016-01-28 | The Board Of Regents Of The University Of Texas System | Use of inhibitors of mtor to improve vascular functions in apoe4 carriers |
| AU2014373683B2 (en) | 2013-12-31 | 2020-05-07 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM982594A0 (en) | 1994-12-02 | 1995-01-05 | University Of Queensland, The | HIV protease inhibitors |
| EP1192177A1 (en) * | 1999-06-15 | 2002-04-03 | Elan Pharmaceuticals, Inc. | Statine-derived tetrapeptide inhibitors of beta-secretase |
-
2002
- 2002-06-12 WO PCT/US2002/019076 patent/WO2002100856A1/en not_active Ceased
- 2002-06-12 US US10/171,182 patent/US6969709B2/en not_active Expired - Fee Related
- 2002-06-12 BR BR0210392-3A patent/BR0210392A/pt not_active IP Right Cessation
- 2002-06-12 CA CA002450202A patent/CA2450202A1/en not_active Abandoned
- 2002-06-12 MX MXPA03011466A patent/MXPA03011466A/es active IP Right Grant
- 2002-06-12 JP JP2003503623A patent/JP2004534064A/ja active Pending
- 2002-06-12 AT AT02752056T patent/ATE323084T1/de not_active IP Right Cessation
- 2002-06-12 ES ES02752056T patent/ES2261699T3/es not_active Expired - Lifetime
- 2002-06-12 EP EP02752056A patent/EP1404671B1/en not_active Expired - Lifetime
- 2002-06-12 DE DE60210614T patent/DE60210614T2/de not_active Expired - Fee Related
-
2005
- 2005-09-02 US US11/218,879 patent/US7442691B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6969709B2 (en) | 2005-11-29 |
| CA2450202A1 (en) | 2002-12-19 |
| ES2261699T3 (es) | 2006-11-16 |
| JP2004534064A (ja) | 2004-11-11 |
| BR0210392A (pt) | 2004-10-13 |
| DE60210614T2 (de) | 2007-03-01 |
| US20060040910A1 (en) | 2006-02-23 |
| ATE323084T1 (de) | 2006-04-15 |
| EP1404671B1 (en) | 2006-04-12 |
| US20030236199A1 (en) | 2003-12-25 |
| DE60210614D1 (de) | 2006-05-24 |
| EP1404671A1 (en) | 2004-04-07 |
| US7442691B2 (en) | 2008-10-28 |
| WO2002100856A1 (en) | 2002-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04000328A (es) | Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer. | |
| TW200512195A (en) | Benzamide 2-hydroxy-3-diaminoalkanes | |
| MXPA04003245A (es) | Hidroxipropilaminas. | |
| MXPA04002785A (es) | Aminas sustituidas para tratamiento de enfermedad de alzheimer. | |
| TW200505418A (en) | Phenacyl 2-hydroxy-3-diaminoalkanes | |
| WO2004022523A3 (en) | 1, 3-diamino-2-hydroxypropane prodrug derivatives | |
| AP2004002952A0 (en) | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds. | |
| MXPA04000338A (es) | Diamindioles para tratamiento de enfermedad de alzheimer. | |
| MXPA04006575A (es) | Amino carboxamidas sustituidas para el tratamiento de la enfermedad de alzheimer. | |
| MXPA03011466A (es) | Macrociclos utiles en tratamiento de enfermedades de alzheimer. | |
| TW200505828A (en) | Substituted ureas and carbamates useful in the treatment of alzheimer's disease | |
| MXPA03011521A (es) | Aminadioles para tratamiento de enfermedad de alzheimer. | |
| MXPA05002420A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos. | |
| UA84407C2 (en) | Acetyl 2-hydroxy-1,3 diaminoalkanes | |
| AU2002314914A1 (en) | Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases | |
| WO2003030886A3 (en) | Allylamides useful in the treatment of alzheimer's disease | |
| AU2002356991A1 (en) | Amino acid derivatives useful for the treatment of alzheimer's disease | |
| BG106293A (en) | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | |
| MXPA03011502A (es) | Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer. | |
| MXPA04000337A (es) | Amindioles para tratamiento de enfermedad de alzheimer. | |
| MXPA03011399A (es) | Metodos para tratar la enfermedad de alzheimer. | |
| WO2002094768A3 (en) | Aza hydroxylated ethyl amine compounds | |
| WO2004029019A3 (en) | Compounds for the treatment of alzheimer’s disease | |
| AU2002362008A1 (en) | Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease | |
| WO2004037179A3 (en) | Substituted peptides useful in the treatment of alzheimer’s disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |